• Users Online: 4471
  • Print this page
  • Email this page
BRIEF COMMUNICATION
Year : 2015  |  Volume : 5  |  Issue : 3  |  Page : 128-131

Rescue effects of intravitreal aflibercept in the treatment of neovascular age-related macular degeneration


1 Department of Ophthalmology, China Medical University Hospital, Taichung, Taiwan
2 Department of Ophthalmology, China Medical University Hospital; School of Medicine, China Medical University, Taichung, Taiwan
3 Department of Ophthalmology, China Medical University Hospital; School of Medicine, China Medical University, Taichung, ; School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan

Correspondence Address:
Chun-Ju Lin
Department of Ophthalmology, China Medical University Hospital, 2 Yuh-Der Road, Taichung City 40447
Taiwan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.1016/j.tjo.2015.05.001

Rights and Permissions

We report the rescue results of intravitreal aflibercept in patients with treatment-resistant neovascular age-related macular degeneration (AMD). We retrospectively analyzed eyes with neovascular AMD resistant to posterior subtenon triamcinolone, intravitreal ranibizumab, and/or bevacizumab treatment in a tertiary medical center in middle Taiwan between December 2013 and October 2014. We then switched treatment to 2.0 mg aflibercept. The main outcome included changes in best-corrected visual acuity and central foveal thickness measured by optical coherence tomography during monthly follow-up. There were 204 patients with neovascular AMD, and the percentage of refractory cases was 1.96% (4 of 204 cases). Our study included five eyes of four patients that were resistant to multiple treatments and subsequently switched to aflibercept. The mean age was 71.25 ± 11.09 years (range 57–83 years). Treatments were on average 6.6 times previously. Upon switching to aflibercept treatment, the average central foveal thickness on optical coherence tomography was 505.6 ± 270.86 μm (range 150–815 μm). After aflibercept treatment, the average central foveal thickness was 192 ± 51.76 μm (range 149–274 μm). All patients showed anatomic improvement, and 80% of the eyes (4 of 5 eyes) had improved best-corrected visual acuity and 20% of the eyes (1 of 5 eyes) had stable visual acuity. Patients tolerated the treatment well without serious adverse events. This short-term study showed that intravitreal aflibercept was effective and safe in treatment-resistant neovascular AMD cases. However, analysis of more cases and long-term follow-ups are mandatory.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1022    
    Printed36    
    Emailed0    
    PDF Downloaded54    
    Comments [Add]    
    Cited by others 3    

Recommend this journal